ANZLG HD3/TROG 99.01 - Hodgkins Disease IFRT - HD3 - TROG Cancer Research

Read our latest Annual Report highlighting TROG achievements

Read our Q & A with TROG Scientific Committee Chair A/Prof Hien Le

Get ready for World Radiotherapy Awareness Day 7 September

TROG ASM2026 - Abstracts now Open

By w.paterson
14 August, 2021
0 Comments

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Related Post

26 August, 2025

Welcome to new TROG committee members and thank you to long-serving members

LATEST NEWS: 26 August 2025 The TROG Scientific Committee

12 August, 2025

TROG 15.03/ANZUP 16001 FASTRACK II: economic analysis shows new technique is cheaper and more effective in the Australian setting

TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer